Lead Product(s): Recombinant coagulation factor IX
Therapeutic Area: Genetic Disease
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Medexus Pharmaceuticals
Deal Size: $30.0 million Upfront Cash: $30.0 million
Deal Type: Acquisition February 28, 2020
Acquisition strengthens Medexus’ specialty product portfolio and represents a strategic fit with other products in the Medexus business development pipeline.